We thank Dr Kronish and his colleagues for their interest in our work. 1 Kronish et al suggest that because of the patient population we studied, our work underestimates the role of noncompliance in aspirin resistance if applied to all patients taking aspirin. 1 However, we did not suggest that the high compliance rate in our study was representative of all patients taking aspirin. The precise incidence of patient noncompliance with aspirin will, of course, vary according to the patient setting. Kronish et al reference their own work and the findings of Cotter et al, 2 who have reported a relatively high (16%) incidence of aspirin noncompliance, but Kronish et al do not reference the findings of Tantry et al, 3 who have reported a low (0.4%) incidence of aspirin noncompliance. Kronish et al acknowledge that, irrespective of the precise incidence of patient noncompliance with aspirin, the novel finding of our study 1 is that there is a residual arachidonic acid-induced platelet activation via an adenosine diphosphate-dependent but cyclooxygenase-1-and cyclooxygenase-2-independent pathway in aspirin-compliant patients.
